Core Viewpoint - The collaboration between Guangzhou Pharmaceutical Group and Ruizhi Pharmaceutical aims to enhance innovation in drug development and establish a competitive biopharmaceutical platform through strategic cooperation and regular communication [1] Group 1: Strategic Collaboration - On January 20, the Vice Secretary of the Party Committee, Vice Chairman, and General Manager of Guangzhou Pharmaceutical Group, Chen Jiehui, led a core team to conduct in-depth research and discussions with Ruizhi Pharmaceutical [1] - The discussions focused on cutting-edge pharmaceutical research technologies, AI intelligent manufacturing, innovative drug development, and market collaboration [1] - Both parties reached a consensus on promoting strategic cooperation and establishing a regular communication mechanism [1] Group 2: Future Development - The two companies will maintain close communication to jointly build a new model for collaborative development in the innovative drug industry [1] - The goal is to create a biopharmaceutical innovation platform with international competitiveness [1]

证券代码：300149 证券简称：睿智医药 公告编号：2026-02 睿智医药科技股份有限公司 关于担保进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 睿智医药科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、 2025 年5 月 30日召开第六届董事会第六次会议、第六届监事会第六次会议和 2024 年年度股东会，审议通过了《关于向银行等金融机构申请综合授信额度并提供担 保的议案》，同意 2025 年度公司为子公司（含子公司之间）提供担保额度合计为 不超过人民币 18,000 万元。具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于向银行等金融机构申请综合授信额度并提 供担保的公告》（公告编号：2025-26）。 公司于 2025 年 9 月 8 日召开第六届董事会第十二次会议，审议通过了《关于 为子公司与关联方开展融资租赁业务提供担保暨关联交易的议案》，为适度利用 融资渠道，优化融资结构，满足经营发展需求，同意公司为全资子公司上海睿智 医 ...

Core Viewpoint - As of January 10, the number of shareholders for Ruizhi Pharmaceutical (300149) reached 39,034 households [1] Company Summary - The company actively engages with investors through interactive platforms, indicating a commitment to transparency and communication [1]

Group 1 - Huaseng Tiancheng's revenue from AI-related business currently accounts for a low proportion of the company's overall operating income [1] - Xinhua Department Store has no plans to inject assets related to semiconductors, integrated circuits, or chips into the company [1] - Triangle Tire plans to invest 3.219 billion yuan to establish a new project in Cambodia with an annual production capacity of 7 million high-performance radial tires [1] Group 2 - Tianhong Co., Ltd.'s subsidiary has won a bid for an AI service procurement project from AVIC Technology [1] - Xinghua New Materials intends to acquire at least 51% of Tian Kuan Technology's shares [1] - Luxshare Precision plans to repurchase company shares worth between 1 billion to 2 billion yuan [1] Group 3 - Rui Zhi Pharmaceutical's Liang Yufeng and Yu Xianwen plan to collectively reduce their holdings by no more than 6% [1] - Tian Sheng New Materials plans to raise no more than 253 million yuan through a private placement to Rongsheng Zhizhi [1] - Zhongchuang Zhiling intends to issue convertible bonds to raise no more than 4.35 billion yuan for investment in high-end components for the new energy vehicle industry [2]

Group 1: Company Strategy - The company's current strategic direction is driven by a "full-package strategy + CVC ecological investment" model, aiming to strengthen its full-chain service capabilities from PCC to IND to NDA while expanding service coverage and technical depth [2] - The company has participated in projects such as the Shenzhen Luohu Donghai Wisdom Pharmaceutical Industry Investment Fund, leveraging its "chain master" role to integrate industry resources and achieve win-win development [3] Group 2: Customer Structure - The customer base is diverse, including multinational pharmaceutical companies (MNCs), biotech firms, and research institutions, with mid-sized biotech companies and MNCs forming the core customer group [4] - These key customers are characterized by stable development, ample funding, and controllable project advancement, providing a solid foundation for the company's ongoing business growth [4] Group 3: AI Technology Integration - The company has over 20 years of R&D experience, utilizing AI technology to enhance research efficiency, shorten development cycles, and reduce the number of candidate compounds, thereby lowering overall R&D costs [4] - A systematic approach is being taken to build a "scientific research intelligent hub platform," improving efficiency in daily operations and applying AI in critical areas such as antibody discovery and drug property prediction [5] Group 4: Nucleic Acid Field Development - The company has established a comprehensive innovative platform covering large and small nucleic acids, with a complete technical system that includes chemical modifications and innovative monomers [6] - Collaborations with companies like Saint Nor Pharmaceutical and Haiyou Biology have been initiated to strengthen capabilities in the nucleic acid sector [7] Group 5: Performance Goals - The three-year stock incentive performance targets have a gradually increasing range due to the initial phase of strategic execution, focusing on overcoming current challenges and key tasks such as the CVC industry fund layout for 2024-2025 [7] - The strategic effects are expected to gradually manifest from 2026 to 2027, leading to an accelerated release cycle of full-package orders, hence the broader performance target range [7]

Acquisitions - Charles River announced the strategic acquisition of K.F. (Cambodia) Ltd. for approximately $510 million, expected to complete in Q1 2026, to self-supply most annual NHP needs[4] - The company will also acquire the remaining 79% of PathoQuest for about €51.60 million (approximately $60 million), expected to contribute $15-20 million in revenue in 2026[4] Supply Chain and Technology Enhancement - The acquisition of K.F. will aid in vertical integration amid global NHP resource constraints, enhancing DSA business stability and cost control[5] - PathoQuest's NGS quality control technology will improve NAMs and bioproduct quality control, increasing the proportion of high-value services[5] DSA Demand Recovery - DSA net book-to-bill ratio reached 1.1x in Q4 2025, up from 0.8x in Q2-Q3 2025, indicating a recovery driven by small and medium biotech demand and growth in large pharma orders[6] - This recovery signals a gradual bottoming out of preclinical demand[6] 2026 Performance Outlook - The company is cautiously optimistic for 2026, expecting organic revenue growth to be at least flat, with DSA business resuming organic growth in H2 2026[6] - Forex is expected to contribute 100-150 basis points to revenue growth[6] Investment Recommendations - Long-term positive outlook on pharmaceutical growth, with a focus on domestic companies such as WuXi AppTec and Pharmaron[7] - Suggested companies to watch include WuXi AppTec, Pharmaron, JOINN Laboratories, and others[7] Risk Factors - Risks include a weaker-than-expected global biotech financing environment and challenges in NHP supply chain recovery[7] - Potential risks related to acquisition integration and project execution[7]

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and investor sentiment in the market [1]. Shareholder Reductions - **New Chai Co., Ltd.**: General Manager Zhu Guanlan plans to reduce holdings by up to 1% [1]. - **Ruizhi Pharmaceutical**: Shareholders Liang Yufeng and Yu Xianwen intend to collectively reduce their stakes by no more than 6% [1]. - **Aidi Te**: Shareholders Junlian Xinkang and HAL plan to reduce their stakes by up to 3% [1]. - **Feiwo Technology**: Shareholder Chang Defuwo intends to reduce holdings by up to 1% [1]. - **Feili Hua**: The actual controller plans to reduce holdings by up to 1% [1]. - **Shanwaishan**: Major shareholder Liu Yunjun plans to reduce holdings by no more than 1% [1]. - **Hongchuan Wisdom**: Shareholder Hongchuan Supply Chain intends to reduce holdings by up to 2% [1]. - **Jiuzhitang**: General Manager Li Zhengguo plans to reduce holdings by no more than 2% [1]. - **Yifan Transmission**: Chairman Liu Jincheng intends to reduce holdings by up to 3% [1]. - **Zhongyuan Home**: Chairman and General Manager Cao Yong plan to collectively reduce holdings by 2.51% [1]. - **Huafeng Aluminum**: Shareholder You Xiaohua has completed a reduction of 2.17% [1]. - **Beijing Renli**: Shareholder Tianjin Rongheng reduced holdings by 6.0399 million shares [1]. - **Hu Silicon Industry**: Major shareholder Da Fund has cumulatively reduced holdings by 0.97% [1]. Other Notable Information - **ST Huawang**: The company's stock may face delisting [1]. - **Kunlun Wanwei**: The company expects a negative net profit attributable to shareholders for the year 2025 [1].

Group 1: Company Announcements - Huasheng Tiancai's AI-related revenue currently accounts for a low proportion of the company's overall operating income [1][2] - Xinhua Department Store has no plans to inject assets related to semiconductors, integrated circuits, or chips into the company [1][2] - Triangle Tire plans to invest 3.219 billion yuan to establish a new project in Cambodia with an annual production capacity of 7 million high-performance radial tires [1][2] Group 2: Contracts and Bids - Tianhong Co., Ltd.'s subsidiary has won a bid for an artificial intelligence service procurement project from AVIC Technology [1][2] - Kaili New Materials has secured a project worth 60.76 million yuan [2] - Zhonghua Rock and Soil's subsidiary has won a bid for a 62.3955 million yuan project related to the maintenance of airport infrastructure in Shanghai [2] Group 3: Equity Transactions - Xinghua New Materials intends to acquire at least 51% of Tian Kuan Technology [1][2] - Ruizi Medicine's Liang Yufeng and Yu Xianwen plan to collectively reduce their holdings by no more than 6% [1][2] - Aidi Te's Junlian Xinkang and HAL plan to reduce their holdings by no more than 3% [2] Group 4: Share Buybacks and Fundraising - Luxshare Precision plans to repurchase shares worth between 1 billion and 2 billion yuan [1][2] - Defu Technology intends to repurchase shares worth between 75 million and 150 million yuan [2] - Tiansheng New Materials plans to raise no more than 253 million yuan through a private placement [1][2] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for investment in high-end components for new energy vehicles [1][2]

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings in the company through centralized bidding or block trading within three months after the announcement [1] Group 1: Shareholder Reductions - Shareholder Liang Yufeng, holding 26,185,660 shares (5.26% of total shares), intends to reduce up to 14,938,919 shares (3% of total shares) [1] - Shareholder Yu Xianwen, holding 25,000,000 shares (5.02% of total shares), also plans to reduce up to 14,938,919 shares (3% of total shares) [1]

Group 1 - The core point of the article is that two major shareholders of Ruizhi Pharmaceutical plan to reduce their holdings in the company by a total of 14,938,919 shares, which represents 3% of the total share capital [2] - Shareholder Liang Yufeng, who holds 26,185,660 shares (5.26% of total shares), intends to sell up to 14,938,919 shares within three months after a 15 trading day period from the announcement date [2] - Shareholder Yu Xianwen, who holds 25,000,000 shares (5.02% of total shares), also plans to reduce his holdings by the same amount of 14,938,919 shares under similar conditions [2]